

**Transient Elastography, Fib-4 score, Lok score
and Fibrosis index score as Non Invasive
Predictors of Oesophageal Varices, its Degree
and Risk of Bleeding in Post Hepatitis C Virus
Liver Cirrhosis**

Thesis

Submitted for Partial Fulfillment of M.D Degree in
Internal Medicine

By

Mohamed Nabil Badawy AL-Ashram

*M.B.B.Ch, M .SC in Internal Medicine
Faculty of Medicine-Ain Shams University*

Under supervision of

Prof. Dr. Ahmed Shawky El Sawaby

Professor of Internal Medicine and Gastroenterology
Faculty of Medicine-Ain Shams University

Prof. Dr. Essam Mohammad Bayomi

Professor of Internal Medicine and Gastroenterology
Faculty of Medicine-Ain Shams University

Prof. Dr. Tarek Mohamed Yousef

Professor of Internal Medicine and Gastroenterology
Faculty of Medicine-Ain Shams University

Ass Prof. Dr. Wesam Ahmed Ibrahim

Assistant Professor of Internal Medicine and Gastroenterology
Faculty of Medicine-Ain Shams University

Dr. Ahmed Ibrahim El Shafie

Lecturer of Internal Medicine and Gastroenterology
Faculty of Medicine-Ain Shams University

**Faculty of Medicine
Ain Shams University**

2016

Abstract

Background: Cirrhosis is the end result of chronic liver damage caused by chronic liver diseases. Common causes of chronic liver disease include Hepatitis C infection (long-term infection), Long-term alcohol abuse, Autoimmune inflammation of the liver, Disorders of the drainage system of the liver (the biliary system), such as primary biliary cirrhosis and primary sclerosing cholangitis, Hepatitis B (long-term infection), Medications, Metabolic disorders of iron and copper (hemochromatosis and Wilson's disease), Nonalcoholic Steatohepatitis (NASH). Egypt has the highest prevalence of hepatitis C virus (HCV) worldwide and a high morbidity and mortality from chronic liver disease. HCV is considered the most common aetiology of chronic liver disease in Egypt. Esophageal varices develop as a consequence of portal hypertension in patients with chronic liver disease and are present in approximately 50% of patients with cirrhosis of the liver.

Aims: To evaluate presence of Esophageal Varices and its degree and risk of bleeding in post HCV liver Cirrhosis using Transient Elastography, Fib-4 score, Lok score and Fibrosis index score as non-invasive procedures in comparison to upper endoscopy findings.

Methodology: This study was a cross sectional study that was conducted on 40 patients with post HCV liver cirrhosis to evaluate presence of Esophageal varices and its degree and risk of bleeding using Transient Elastography, Fib-4 score, Lok score and Fibrosis index score as non invasive procedures in comparison to upper endoscopy findings. Patients were selected from Ain Shams University hospitals in the period from (June 2014) to (December 2015).

Results: Those 40 patients were divided into 2 groups: Group 1: 15 patients with liver cirrhosis (Child A). Group 2: 25 Patients with advanced liver cirrhosis (Child B, C). 18 patients were Child B and 7 patients were Child C.

Conclusion: LSM and LOK score have significant correlation with EV risk of bleeding and can be used as non invasive markers to predict and follow up risky EVs which will need intervention by endoscopy. LSM and LOK score are sensitive and reliable tests in prediction of large and risky EVs.

Recommendations: Although Upper gastrointestinal endoscopy is the gold standard for diagnosis of esophageal varices size, grading and risk of bleeding in newly diagnosed patients with liver cirrhosis. LSM and LOK score can be used for prediction and follow up esophageal varices as regards risk of bleeding. We recommend to do upper endoscopy as soon as possible for patients with liver cirrhosis if LSM >46 kpa and Lok score > 0.86 as they mostly have large risky EVs which will need prophylactic intervention before bleeding occurs.

Keywords: Transient Elastography, Fib-4 score, Lok score and Fibrosis index score, Esophageal Varices, Hepatitis C Virus, Liver Cirrhosis


بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سُبْحَانَكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا عَلِمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



ACKNOWLEDGEMENT

*First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work,*

*Really I can hardly find the words to express my gratitude to **PROF. DR. AHMED SHAWKY EL SAWABY** Professor of Internal Medicine, Faculty of Medicine Ain Shams University, for his supervision, continuous help, encouragement throughout this work and tremendous effort he has done in the meticulous revision of the whole work. It is a great honor to work under his guidance and supervision.*

*I would like to express my thanks and appreciation to **PROF. DR. ESSAM MOHAMED BAYOMI** Professor of Internal Medicine Faculty of Medicine Ain Shams University, for his guidance and sincere supervision of this work,*

*I am also indebted to **PROF. DR. TAREK YOUSEF** Professor of Internal Medicine Faculty of Medicine Ain Shams University, for his guidance, continuous assistance and sincere supervision of this work,*

*Also I have a lot of thanks to **ASSISTANT PROF. DR. WESAM AHMED IBRAHIM** Assistant Professor of Internal Medicine Faculty of Medicine Ain Shams University, for her continuous help and sincere advices.*

*I can not forget **DR. AHMED IBRAHIM EL SHAFIE** lecturer of Internal Medicine Faculty of Medicine Ain Shams University, for his great effort and sincere revision to every step in this work .*

Last but not least ,I dedicate this work to soul of my Father and Mother who have a great favour on me. Also I dedicate it to my dear wife whom without her sincere emotional support and pushing me forward this work would not have ever been completed.

Contents

Subjects	Page
List of abbreviations.....	II
List of Figures.....	V
List of Tables.....	VII
• Introduction	1
• Aim of the Work	7
• Review of Literature	
♦ Chapter (1): Hepatitis C virus.....	8
♦ Chapter (2): Esophageal varices.....	41
♦ Chapter (3): Non invasive assessment of esophageal varices.....	78
• Patients and Methods	98
• Results	107
• Discussion	130
• Summary and Conclusion	142
• Recommendations	145
• References	146
• Arabic Summary	

List of Abbreviations

AASLD:	American Association for the Study of Liver Diseases.
AFP:	Alfa fetoprotein.
AIH:	Auto immune hepatitis.
ALD:	Alcoholic Liver disease.
ALF:	Acute liver failure.
ALT:	Alanine transaminase.
APRI:	AST to Platelet ratio index.
AST:	Aspartate transaminase.
BMI:	Body mass index.
BP:	Blood pressure.
bpm:	Beat per minute.
BUN:	Blood urea nitrogen.
CBC:	Complete blood count.
CDC:	Center for disease control.
CHB:	Chronic hepatitis B.
CHC:	Chronic hepatitis C.
CSPH:	Clinically significant portal hypertension.
CTP:	Child-Turcott-Pugh.
ECG:	Electrocardiography.
EDHS:	Egyptian Demographic Health Survey
EGD:	Esophagogastroduodenoscopy.

List of Abbreviations

EUS:	Endoscopic ultrasound.
EVs:	Esophageal varices.
FDA:	Food and Drug administration.
FIS:	Fibrosis index score.
HBV:	Hepatitis B virus.
HCC:	Hepatocellular carcinoma.
HCV:	Hepatitis C virus.
HIV:	Human immunodeficiency virus.
HR:	Heart rate.
HTN:	Hypertension.
HVPG:	Hepatic venous pressure gradient.
IDSA:	Infectious Diseases Society of America.
IDU:	Intravenous drug use.
INR:	International normalized ratio.
IRES:	Internal ribosome entry site
ISMN:	Isosorbide mononitrate.
IVC:	Inferior vena cava.
LB:	Liver biopsy.
LC:	Liver cirrhosis.
LDL:	Low density lipoprotein.
LEV:	Large esophageal varices.
LSM:	Liver stiffness measurement.
MELD:	Model for end-stage liver disease.
NAFLD:	Non alcoholic liver disease.

List of Abbreviations

NASH:	Non alcoholic steatohepatitis.
NPV:	Negative predictive value.
NSBB:	Non cardioselective beta blocker.
PAT:	Parenteral-antischistosomal-therapy.
PBC:	Primary Biliary Cirrhosis.
PCR:	Polymerase chain reaction.
PEG-IFN:	Pegylated interferon.
PHT:	Portal hypertension.
PPG:	Portal pressure gradient.
PPV:	Positive predictive value.
PSC:	Primary sclerosing cholangitis.
PT:	Prothrombin time.
PTFE:	Polytetra flouroethylene.
PTT:	Partial thromboplastin time.
RCT:	Randomised controlled trial.
SD:	Standard deviation.
SE:	Sensitivity.
SP:	Specificity.
SVR:	Sustained virological responses.
TE:	Transient elastography.
TIPS:	Transjugular intrahepatic portosystemic shunt.
UGIB:	Upper Gastro Intestinal Bleeding.
WGO:	World gastroenterology organization.
WHO:	World health organization.

List of Figures

Fig. No.	Title	Page No.
1	HCV structure	9
2	HCV RNA	11
3	HCV replication steps	17
4	Gastroscopy image of esophageal varices with prominent cherry-red spots.	49
5	Classification of Esophageal varices	51
6	Classification of Esophageal varices	51
7	Algorithm for surveillance of varices and primary prophylaxis in cirrhosis.	62
8	Algorithm for the management of acute variceal bleeding.	72
9	Examples of liver stiffness measurements.	80
10	A noninvasive algorithm for the assessment of esophageal varices in patients with liver cirrhosis.	97
11	Example of the technique of Fibroscan.	102
12	Correlation between Liver stiffness, fibrosis stage and liver disease.	103
13	Comparison between both groups as regards sex.	108
14	Comparison between both groups as regards age.	109
15	Comparison between both groups as regards Liver stiffness.	114
16	Comparison between both groups as regards Fib 4 score.	115

List of Figures

Fig. No.	Title	Page No.
17	Comparison between both groups as regards FIS score.	116
18	Comparison between both groups as regards LOK score.	117
19	Comparison between both groups as regards prescence of esophageal varices.	119
20	ROC curve for the diagnostic performance of LSM,Fib4,FIS AND LOK score in EV detection.	121
21	Comparison between both groups as regards esophageal varices risk of bleeding.	122
22	ROC curve for the diagnostic performance of LSM,Fib4,FIS AND LOK score in EV risk detection.	124
23	Comparison between both groups as regards esophageal varices degree.	125
24	ROC curve for the diagnostic performance of LSM,Fib4,FIS AND LOK score in Small EV detection.	127
25	ROC curve for the diagnostic performance of LSM,Fib4,FIS AND LOK score in Medium EV detection.	128
26	ROC curve for the diagnostic performance of LSM,Fib4,FIS AND LOK score in Large EV detection.	129

List of Tables

Table No.	Title	Page No.
1	Epidemiology of EVs and correlation with liver disease	46
2	Correlation between the presence of varices and the severity of liver disease	47
3	Comparison between both groups as regards sex.	108
4	Comparison between both groups as regards sex.	109
5	Comparison between both groups as regards CBC.	110
6	Comparison between both groups as regards LFTs.	111
7	Comparison between both groups as regards liver enzymes.	112
8	Comparison between both groups as regards KFTs.	112
9	Comparison between both groups as regards PV diameter and velocity.	113
10	Comparison between both groups as regards Liver stiffness.	114
11	Comparison between both groups as regards Fib 4 score.	115
12	Comparison between both groups as regards FIS score.	116
13	Comparison between both groups as regards LOK score.	117
14	Comparison between different Child score and liver stiffness, Fib 4, FIS and LOK score.	118

List of Figures

Table No.	Title	Page No.
15	Comparison between both groups as regards prescence of esophageal varices.	119
16	Comparison between prescence of EV and liver stiffness, Fib 4, FIS and LOK score.	120
17	The diagnostic performance of LSM, Fib4, FIS AND LOK score in EV detection	121
18	Comparison between both groups as regards esophageal varices risk of bleeding.	122
19	Comparison between EV risk of bleeding and liver stiffness, Fib 4, FIS and LOK score.	123
20	Correlation between EV risk of bleeding and LV Stiffness, Fib4, FIS and LOK score.	123
21	The diagnostic performance of LSM, Fib4, FIS AND LOK score in EV risk detection.	124
22	Comparison between both groups as regards esophageal varices degree.	125
23	comparison between EV degree and LSM,Fib4,Lok score and FIS .	126
24	The diagnostic performance of LSM, Fib4, FIS AND LOK score in Small EV detection.	127
25	The diagnostic performance of LSM, Fib4, FIS AND LOK score in Medium EV detection.	128
26	The diagnostic performance of LSM, Fib4, FIS AND LOK score in Large EV detection.	129

Introduction

Cirrhosis is the end result of chronic liver damage caused by chronic liver diseases. Common causes of chronic liver disease include Hepatitis C infection (long-term infection), Long-term alcohol abuse, Autoimmune inflammation of the liver, Disorders of the drainage system of the liver (the biliary system), such as primary biliary cirrhosis and primary sclerosing cholangitis, Hepatitis B (long-term infection), Medications, Metabolic disorders of iron and copper (hemochromatosis and Wilson's disease), Nonalcoholic Steatohepatitis (NASH) (*Schuppan and Afdhal., 2008*).

Chronic hepatitis C virus (HCV) infection is a major public health problem (*Shaheen and Myers., 2007*). It is estimated that 180 million people worldwide are chronically infected with HCV (*Ghany et al., 2009*). Chronic HCV infection is the major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma in developed countries (*Sebastiani et al., 2008; Ghany et al., 2009*). Cirrhosis from chronic HCV infection is also the most common indication for liver transplantation (*Cheung et al., 2008*).

Egypt has the highest prevalence of hepatitis C virus (HCV) worldwide and a high morbidity and mortality from chronic liver disease (*Lavanchy and McMahon., 2000*). HCV is considered the most common aetiology of chronic liver disease in Egypt. Esophageal varices develop as a consequence of portal hypertension in patients with chronic liver disease and are present in approximately 50% of patients with cirrhosis of the liver (*Strickland et al., 2002*).

Bleeding oesophageal varices is the gravest complication of liver cirrhosis, with a high mortality (*D'Amico et al., 2006*). Each variceal bleeding attack carries a mortality rate of 17%-57% (*Merkel et al., 2004*). Prevention of variceal bleeding vital, while non-selective beta blockers and prophylactic band ligation decrease the risk of bleeding by 50% (*Imperiale and Chalasani., 2001*). The grade of esophageal varices often correlates with the severity of liver disease. While approximately 85% of individuals with Child-Pugh C cirrhosis have varices, they are present in only 45% those with Child-Pugh A cirrhosis.

Upper gastrointestinal endoscopy is the best method for evaluating the presence of complication of portal hypertension including gastroesophageal varices and portal hypertensive gastropathy, and its routinely employed as a first-level approach to assess this syndrome (*Grace et al., 1998*). Indeed, esophageal varices are present in about 40%

of compensated cirrhotic patients and in 60% of those presenting with ascites at the initial diagnosis of cirrhosis (*Schepis et al., 2001*).

Moreover, upper gastrointestinal endoscopy discloses the characteristics of the varices (i.e. dimension and presence of red signs). Detection of these signs offers important predictive information for the occurrence of variceal bleeding (*Merkel et al., 2000*). Additionally, upper gastrointestinal endoscopy allows to assess the presence, extent, and severity of portal hypertension gastropathy.

The current guidelines recommend endoscopic screening to all cirrhotic patients. Those with decompensated cirrhosis should annually repeat endoscopy even if they have no varices, while those with compensated cirrhosis and don't have varices should repeat endoscopy every 2-3 years, and every 1-2 years for those with small varices (*Grace et al., 1998*). The annual incidence of variceal bleeding is 5% for small varices and 15–20% for large ones with portal pressure greater than 12 mm Hg, both with mortality rates ranging from 20 to 25% in the first week (*Sharma and Aggarwal., 2007*). The risk of death remains unchanged for up to 6 weeks after the bleeding and varies between 15 and 30% (*De Franchis et al., 2008*).